Canada Clears Phase 1 Trial of Moderna’s New Ebola Vaccine Targeting a Virus Strain With No Approved Vaccine
mRNA-1469 will be evaluated in healthy adults for safety, tolerability, and immune response for the first time; the trial does not mean the vaccine has been approved for market, but it is a critical starting point for closing the preparedness gap against Bundibugyo ebolavirus.